Europe's ability to produce vital antibiotics is under severe threat from a deluge of low-cost imports from China, the chief executive of pharmaceutical giant Sandoz has cautioned. He warned that without more robust protective measures, the continent risks a significant erosion of its capacity to manufacture these critical medicines, potentially leaving nations, including the United Kingdom, exposed to future supply disruptions.
Richard Saynor, CEO of Sandoz, a leading generic drug manufacturer, highlighted that the current market dynamics make it increasingly difficult for European companies to compete. The lower production costs associated with Chinese manufacturing allow imported antibiotics to be sold at prices that domestic producers struggle to match, leading to an unsustainable environment for European facilities. This trend jeopardises the long-term viability of local production bases.
The implications for the UK are considerable, given its reliance on a complex global supply chain for a vast array of essential medicines. While the UK does not produce all its own antibiotics, it benefits from a diverse European manufacturing base. A decline in this capacity would increase the UK's dependence on non-European suppliers, potentially exacerbating vulnerabilities during global health crises or geopolitical instability.
The issue extends beyond simple economics, touching upon national health security and resilience. The COVID-19 pandemic underscored the fragilities within global supply chains, particularly concerning medical supplies. Losing the capacity to produce fundamental medicines like antibiotics within Europe would represent a significant step backwards in building pharmaceutical independence and preparedness for future health challenges.
Industry leaders and policymakers are now being urged to consider strategic interventions. These could include a range of measures such as preferential procurement policies for European-made medicines, investment in domestic manufacturing capabilities, or tariffs on certain imports to level the playing field. The aim would be to ensure that Europe retains sufficient capacity to safeguard its citizens' access to essential treatments, rather than becoming overly reliant on a single region for critical supplies.
The Government and the National Health Service (NHS) consistently monitor medicine supplies and work to mitigate potential shortages. However, a systemic weakening of the European manufacturing base would add significant pressure to these efforts, requiring a proactive approach to prevent a future crisis in antibiotic availability. Opposition parties are likely to scrutinise the Government's strategy for ensuring medicine security in light of these warnings.
Source: Sandoz